NCT02399371View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With Malignant Mesothelioma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 20, 2026

Study Completion Date

March 20, 2026

Conditions
Biphasic MesotheliomaEpithelioid MesotheliomaPeritoneal Malignant MesotheliomaPleural Biphasic MesotheliomaPleural Epithelioid MesotheliomaPleural Malignant MesotheliomaPleural Sarcomatoid MesotheliomaRecurrent Peritoneal Malignant MesotheliomaRecurrent Pleural Malignant MesotheliomaSarcomatoid Mesothelioma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER